Celltrion’s New Quadruple Agonist Obesity Drug Outperforms Retatrutide in Early Testing
The experimental quadruple agonist showed greater weight loss and less relative lean-mass loss in animal studies. Human trials could begin in 2027.
On The Pen | GLP-1 & Obesity Medicine News
On The Pen Patient Tool
Find My Trial
Find obesity and metabolic clinical trials that may be relevant to you, then connect directly with the study team when contact information is available.
Find My Trial18,188 recruiting studies tracked across 1086 treatments — sourced from ClinicalTrials.gov.
Top Stories
The most-read On The Pen stories, ranked by reader engagement.
REBRAND: Novo Drops the Nordisk, Flip Its Logo, but Can It Flip the GLP-1 Race?
Novo will aslo add the tagline “Lasting health starts now”… Here’s how they could actually make that a reality.
Latest News
Retatrutide Doubles Ozempic Weight Loss, but There’s a Lot More to the Story
Lilly’s triple agonist produced about 20% to 21% weight loss in people with type 2 diabetes, more than double Ozempic 2 mg. But the dose comparison, and what happened as retatrutide doses climbed, deserve just as much attention.
The Weekly Dose
On The Pen's flagship podcast — obesity medicine, unfiltered.
Recent Livestreams
Obesity.News
Stay ahead of obesity medicine.
Breaking GLP-1 news, drug development, access updates, and patient-centered analysis, all in one place.
- Breaking obesity medicine and GLP-1 news
- The latest from The Weekly Dose podcast
- Live talk show every Monday, Wednesday, and Friday at 11 AM CT
- Deeper reporting and analysis for paid subscribers
Empowering you to have better conversations with your doctor.
On The Pen covers obesity medicine from the patient's side of the exam table — GLP-1s, access, and the science, reported plainly.
Sponsors & Partners